(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 98.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Nuvation Bio's revenue in 2026 is $62,902,000.On average, 13 Wall Street analysts forecast NUVB's revenue for 2026 to be $61,823,653,822, with the lowest NUVB revenue forecast at $36,257,873,216, and the highest NUVB revenue forecast at $78,581,319,124. On average, 11 Wall Street analysts forecast NUVB's revenue for 2027 to be $118,593,243,061, with the lowest NUVB revenue forecast at $75,658,025,924, and the highest NUVB revenue forecast at $147,593,284,882.
In 2028, NUVB is forecast to generate $170,757,168,221 in revenue, with the lowest revenue forecast at $106,635,896,319 and the highest revenue forecast at $251,312,839,947.